These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 6309904)
21. Prevention of nerve conduction deficit in diabetic rats by polyunsaturated fatty acids. Head RJ; McLennan PL; Raederstorff D; Muggli R; Burnard SL; McMurchie EJ Am J Clin Nutr; 2000 Jan; 71(1 Suppl):386S-92S. PubMed ID: 10618002 [TBL] [Abstract][Full Text] [Related]
22. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat. Stevens MJ; Lattimer SA; Feldman EL; Helton ED; Millington DS; Sima AA; Greene DA Metabolism; 1996 Jul; 45(7):865-72. PubMed ID: 8692023 [TBL] [Abstract][Full Text] [Related]
24. Glutathione redox state is not the link between polyol pathway activity and myo-inositol-related Na+-K+-ATPase defect in experimental diabetic neuropathy. Carroll PB; Thornton BM; Greene DA Diabetes; 1986 Nov; 35(11):1282-5. PubMed ID: 3019809 [TBL] [Abstract][Full Text] [Related]
26. Na+-K+-ATPase pumping activity is not directly linked to myo-inositol levels after sorbinil treatment in lenses of diabetic rats. Yeh LA; Rafford CE; Goddu KJ; Ashton MA; Beyer TA; Hutson NJ Diabetes; 1987 Dec; 36(12):1414-9. PubMed ID: 2824260 [TBL] [Abstract][Full Text] [Related]
27. Protein kinase C agonists acutely normalize decreased ouabain-inhibitable respiration in diabetic rabbit nerve. Implications for (Na,K)-ATPase regulation and diabetic complications. Greene DA; Lattimer SA Diabetes; 1986 Feb; 35(2):242-5. PubMed ID: 3002888 [TBL] [Abstract][Full Text] [Related]
28. Selective effects of myo-inositol administration on sciatic and tibial motor nerve conduction parameters in the streptozocin-diabetic rat. Greene DA; Lewis RA; Lattimer SA; Brown MJ Diabetes; 1982 Jul; 31(7):573-8. PubMed ID: 7160537 [TBL] [Abstract][Full Text] [Related]
29. Relation of Na+, K(+)-ATPase to delayed motor nerve conduction velocity: effect of aldose reductase inhibitor, ADN-138, on Na+, K(+)-ATPase activity. Hirata Y; Okada K Metabolism; 1990 Jun; 39(6):563-7. PubMed ID: 2161992 [TBL] [Abstract][Full Text] [Related]
30. Adenosine triphosphatase in nerves and ganglia of rats with streptozotocin-induced diabetes or galactosaemia; effects of aldose reductase inhibition. Lambourne JE; Brown AM; Calcutt N; Tomlinson DR; Willars GB Diabetologia; 1988 Jun; 31(6):379-84. PubMed ID: 2970984 [TBL] [Abstract][Full Text] [Related]
31. A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats. Yasuda H; Sonobe M; Hisanaga T; Kawabata T; Maeda K; Kikkawa R; Shigeta Y Metabolism; 1992 Jul; 41(7):778-82. PubMed ID: 1320179 [TBL] [Abstract][Full Text] [Related]
33. A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: relationship to myo-inositol metabolism and nerve conduction slowing. Greene DA Metabolism; 1986 Apr; 35(4 Suppl 1):60-5. PubMed ID: 2421135 [TBL] [Abstract][Full Text] [Related]
34. Reduced Na+ + K+-ATPase activity in peripheral nerve of streptozotocin-diabetic rats: a role for protein kinase C? Simpson CM; Hawthorne JN Diabetologia; 1988 May; 31(5):297-303. PubMed ID: 2840314 [TBL] [Abstract][Full Text] [Related]
35. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Coppey LJ; Gellett JS; Davidson EP; Dunlap JA; Lund DD; Salvemini D; Yorek MA Br J Pharmacol; 2001 Sep; 134(1):21-9. PubMed ID: 11522593 [TBL] [Abstract][Full Text] [Related]
36. Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol. Greene DA; Chakrabarti S; Lattimer SA; Sima AA J Clin Invest; 1987 May; 79(5):1479-85. PubMed ID: 3033025 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. Obrosova IG; Van Huysen C; Fathallah L; Cao X; Stevens MJ; Greene DA FASEB J; 2000 Aug; 14(11):1548-58. PubMed ID: 10928989 [TBL] [Abstract][Full Text] [Related]
38. Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol. Tomlinson DR; Mayer JH Exp Neurol; 1985 Aug; 89(2):420-7. PubMed ID: 2410289 [TBL] [Abstract][Full Text] [Related]
39. Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Goldfarb S; Ziyadeh FN; Kern EF; Simmons DA Diabetes; 1991 Apr; 40(4):465-71. PubMed ID: 2010046 [TBL] [Abstract][Full Text] [Related]
40. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor. Greene DA; Lattimer SA Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]